BioMarin Pharmaceutical Inc. seems interested in taking advantage of the precedent Center for Drug Evaluation and Research Director Janet Woodcock created with her approval of Sarepta Therapeutics Inc.'s Duchenne muscular dystrophy treatment Exondys 51 (eteplirsen).
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?